GBC CellBio™ is an automated liquid biopsy platform that captures and harvests circulating tumor cells (CTCs) — and other rare/abnormal cells — from a standard blood draw for clinical research and translational applications. Because collection is non-invasive and repeatable, CellBio™ enables longitudinal, real-time insights into tumor biology for screening, therapy monitoring, and precision care.

Unlike ctDNA tests, which are limited to nucleic acids, intact CTCs preserve cellular morphology and multi-omic signals (DNA/RNA/protein), supporting cytology, immunostaining, and molecular profiling on the same sample to inform oncology and pathology workflows.

Circulating tumor cells are rare cancer cells that leave the primary tumor and enter the bloodstream. Studying CTCs can reveal tumor burden, phenotype (epithelial/mesenchymal), and molecular changes associated with progression and treatment response.

CellBio™ uses a microfluidic, size/deformability-based capture approach to enrich intact CTCs directly from whole blood, then harvests them for downstream assays (e.g., immunostaining, FISH, qPCR, NGS, cell culture). This marker-independent workflow supports diverse CTC phenotypes and reduces hands-on steps, streamlining rare-cell analysis.

CellBio™ delivers an automated, lab-friendly workflow to capture intact CTCs and other rare cells without complex pre-processing, supporting fast turnaround and reliable results for oncology and pathology teams.

Key benefits:
• Fast, streamlined workflow — non-invasive blood sample in; enriched cells out; minimal hands-on time
• Marker-independent capture — supports epithelial, mesenchymal, and clustered CTCs
• Intact cells for multi-omics — perform morphology + IF/IHC + FISH + qPCR + NGS + culture on the same sample
• Quality built-in — checkpoints and standardized reagents help ensure run-to-run consistency
• Scalable throughput — flexible configurations for small batches or higher-volume runs

System capacity:
• CellBio™ a2000 — up to 2 samples per run
• CellBio™ FX10 — up to 10 samples per run


CellBio™ Dx Reagent Kit

Designed to complement the CellBio™ workflow:
• iFiltration™ Unit
• Prefixation Buffer
• Positive Control
• Fixation/Permeabilization Buffer
• Mounting Solution with DAPI
• Staining Solution
• Concentrated Washing Solution (20×)

What We Do
• CTC and cluster detection and enumeration
Detection and counting of epithelial, mesenchymal, and carcinoma-type CTCs, as well as CTC clusters with morphology-based review.
• Phenotyping and imaging
High-quality microscopy with immunofluorescence or IHC panels, providing curated image sets for deeper insights.
• Molecular analysis
Flexible downstream workflows including FISH, qPCR/RT-qPCR, and NGS for DNA/RNA profiling.
• Custom research services
Study-specific method development, assay optimization, and protocol customization. We also support companion diagnostics and exploratory biomarker studies.

How It Works
1. Project scoping – Define study goals, markers, and analytical endpoints including enumeration, IF/IHC, FISH, qPCR, or NGS.
2. Collection and logistics – Provide validated blood collection kits and SOPs to ensure sample integrity during transit.
3. CellBio™ enrichment – Automated, marker-independent capture of intact CTCs suitable for both cytology and multi-omics.
4. Analysis and reporting – Deliver standardized reports including CTC counts, images, QC metrics, and assay methods. Optional raw data packages are available.
5. Review and optimization – Optional consultation with our scientists to refine protocols or scale up for multi-site studies.


What You Receive
• Comprehensive study report including counts, representative images, assay methods, and QC metrics
• Optional data package including images, processed results, and raw genomics data for deeper analysis
• Operational flexibility to support pilot studies, larger clinical programs, or technology transfer for partner labs

Regulatory note: Services are provided for research use only (RUO) unless otherwise specified.


Collaboration Opportunities

We collaborate with biopharma companies, CROs, insurers, biotech innovators, and clinical laboratories to unlock rare-cell insights and co-develop advanced diagnostic strategies.
[CONTACT US] to discuss your project.